By Brian Amaral (January 26, 2017, 4:26 PM EST) -- GlaxoSmithKline plc asked a Massachusetts federal judge on Thursday to dismiss fraud-based claims from multidistrict litigation connecting the anti-nausea drug Zofran to birth defects, arguing that the master complaint is devoid of details about any alleged lies and obfuscations.
The master complaint doesn't give the who, what, when, where or why to get past Rule 9(b) dismissal and engages in a "fishing expedition" on fraud in marketing or labeling the drug, the company told U.S. District Judge F. Dennis Saylor IV.
"The rule demands that plaintiffs plead time, place and content of any false representation," Jennifer Stevenson of Shook Hardy &...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!